SCHEMBL104815

SCHEMBL104815

CC(C)NC(=O)C1CCCCC1

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.56
MEN1 O00255 1/20 0.56
KMT2A Q03164 1/20 0.56
HDAC8 Q9BY41 1/20 0.56
HDAC6 Q9UBN7 1/20 0.56
LMNA P02545 2/20 0.51
HPGD P15428 2/20 0.51
TSHR P16473 2/20 0.51
POLB P06746 1/20 0.51
CHRNB2 P17787 1/20 0.50
CHRNB4 P30926 1/20 0.50
CHRNA3 P32297 1/20 0.50
CHRNA7 P36544 1/20 0.50
CHRNA4 P43681 1/20 0.50
RECQL P46063 1/20 0.50
GAA P10253 1/20 0.47
EPHX1 P07099 1/20 0.47
MAPK1 P28482 1/20 0.46
HTT P42858 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18935418 1.00 SMN1; SMN2 (0.56) SMN1; SMN2MEN1KMT2AHDAC8HDAC6
SCHEMBL24997854 1.00 SMN1; SMN2 (0.56) SMN1; SMN2MEN1KMT2AHDAC8HDAC6
SCHEMBL18935499 1.00 SMN1; SMN2 (0.56) SMN1; SMN2MEN1KMT2AHDAC8HDAC6
SCHEMBL24997802 1.00 SMN1; SMN2 (0.56) SMN1; SMN2MEN1KMT2AHDAC8HDAC6
SCHEMBL1940413 0.98 SMN1; SMN2 (0.55) SMN1; SMN2MEN1KMT2AHDAC8HDAC6
Hydrochloric Acid SCHEMBL573477 0.98 SMN1; SMN2 (0.55) SMN1; SMN2MEN1KMT2AHDAC8HDAC6
SCHEMBL1703385 0.98 SMN1; SMN2 (0.58) SMN1; SMN2MEN1KMT2AHDAC8HDAC6
SCHEMBL12375164 0.93 SMN1; SMN2 (0.58) SMN1; SMN2MEN1KMT2AHDAC8HDAC6
SCHEMBL172134 0.90
SCHEMBL10076786 0.90 SMN1; SMN2 (0.60) SMN1; SMN2MEN1KMT2AHDAC8HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 262 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024099402-A1 INTERMEDIATES AND PROCESS OF COMPOUNDS FOR THE DEGRADATION OF EGFR KINASE BEIGENE (BEIJING) CO., LTD. (CN) 2024-05-16 WO claimed
EP-3027604-A2 NOVEL QUINAZOLINONES AS BROMODOMAIN INHIBITORS Zenith Epigenetics Corp. (CA) 2016-06-08 EP claimed
WO-1995024404-A1 PREPARATION OF SYMMETRICAL AND UNSYMMETRICAL DITHIIN COMPOUNDS SHAMAN PHARMACEUTICALS, INC. (US) 1995-09-14 WO claimed
US-12036209-B2 Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides ARVINAS OPERATIONS, INC. (US) 2024-07-16 US disclosed
US-20240208968-A1 ALPHA V BETA 6 AND ALPHA V BETA 1 INTEGRIN INHIBITORS AND USES THEREOF DICE MOLECULES SV, INC. 2024-06-27 US disclosed
WO-2024099402-A1 INTERMEDIATES AND PROCESS OF COMPOUNDS FOR THE DEGRADATION OF EGFR KINASE BEIGENE (BEIJING) CO., LTD. (CN) 2024-05-16 WO disclosed
WO-2024064363-A2 LIGNIN-BASED BIODEGRADABLE POLYMERS AND METHODS OF MAKING THE SAME The Florida State University Research Foundation, Inc. (US) 2024-03-28 WO disclosed
WO-2024064361-A1 LIGNIN-BASED BIODEGRADABLE POLYMERS AND METHODS OF MAKING THE SAME The Florida State University Research Foundation, Inc. (US) 2024-03-28 WO disclosed
US-11857519-B2 Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide ARVINAS OPERATIONS, INC. (US) 2024-01-02 US disclosed
US-20230353959-A1 PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF RELAY THERAPEUTICS, INC. 2023-11-02 US disclosed
US-20230353959-A1 PI3K-ALPHA INHIBITORS AND METHODS OF USE THEREOF RELAY THERAPEUTICS, INC. 2023-11-02 US disclosed
US-5587393-A ANGIOTENSIN ANTAGONIST USEFUL IN TREATING HYPERTENSION DR. KARL THOMAE GMBH (DE) 1996-12-24 US disclosed
WO-1995024404-A1 PREPARATION OF SYMMETRICAL AND UNSYMMETRICAL DITHIIN COMPOUNDS SHAMAN PHARMACEUTICALS, INC. (US) 1995-09-14 WO disclosed
US-5385925-A Benzimidazoles, pharmaceutical compositions containing these compounds and processes for preparing them DR. KARL THOMAE GMBH (DE) 1995-01-31 US disclosed
WO-1991014689-A1 ANTIMALARIAL ANALOGS OF ARTEMISININ SRI INTERNATIONAL (US) 1991-10-03 WO disclosed
EP-0229007-B1 ANTICONVULSANT GAMMA-THIOBUTYROLACTONE DERIVATIVES WASHINGTON UNIVERSITY (US) 1990-11-28 EP disclosed
US-4707491-A Anticonvulsant γ-thiobutyrolactone derivatives WASHINGTON UNIVERSITY (US) 1987-11-17 US disclosed
EP-0229007-A1 Anticonvulsant gamma-thiobutyrolactone derivatives WASHINGTON UNIVERSITY (US) 1987-07-15 EP disclosed
EP-0188185-A1 Novel n-acyl-isopropylglycine derivatives Monsanto Company (US) 1986-07-23 EP disclosed
EP-0027020-A1 2-Substituted-4-alkyl or trihaloalkyl-5-oxazolecarboxylic acid derivatives, their use as safening agents and herbicidal compositions containing them MONSANTO COMPANY (US) 1981-04-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240208968-A1 ALPHA V BETA 6 AND ALPHA V BETA 1 INTEGRIN INHIBITORS AND USES THEREOF ITGB1, ITGA1, ITGAV SMN1; SMN2 2217/4885MEN1 2072/4885KMT2A 3333/4885
US-12036209-B2 Compounds and methods for the targeted degradation of Interleukin-1 receptor-associated kinase 4 polypeptides IRAK1, IRAK4, IRAK2 SMN1; SMN2 1811/4885MEN1 2168/4885KMT2A 2172/4885
US-11857519-B2 Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide CRBN, MDM2, VHL SMN1; SMN2 881/4885MEN1 1376/4885KMT2A 754/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.